Rossari Biotech LimitedQ2 FY27 Results & Financial Update
Rossari Biotech Limited: Q2 FY27 consolidated results and company financials – revenue ₹697.56 Cr, PAT ₹38.91 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Rossari Biotech price & chart
Market price₹419.95
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Rossari Biotech Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Rossari Biotech Limited reported consolidated revenue from operations of INR 697.56 crore for the quarter ended September 30, 2026, remaining stable compared to INR 697.20 crore recorded in the preceding quarter ended June 30, 2026.
Total income for Q2 FY27 stood at INR 698.159 crore, moving alongside top-line revenue with other income contributing INR 0.599 crore and interest income adding INR 0.882 crore during the period.
Profit before tax (PBT) for the quarter improved sequentially to INR 48.80 crore compared to INR 47.672 crore in Q1 FY27, representing a modest increase in pre-tax earnings.
Profit after tax (PAT) expanded more notably to INR 38.907 crore for Q2 FY27, up 10.86 percent from INR 35.095 crore in the previous quarter, aided by tax adjustments.
Basic and diluted earnings per share (EPS) for the quarter rose correspondingly to INR 7.02 compared to INR 6.34 in the June 2026 quarter.
Tax expense for the current quarter was reported at INR 10.362 crore against a backdrop of steady operational performance and financing charges.
Finance costs for Q2 FY27 were recorded at INR 8.677 crore, while depreciation and amortization expenses stood at INR 30.096 crore.
01 · Business model
What does Rossari Biotech do?
Rossari Biotech Limited operates as a specialty chemicals manufacturer, delivering customized chemical solutions across diverse end-user industries including home care, personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition.
The company's operating model combines in-house research and development with scalable manufacturing infrastructure, allowing it to formulate tailored chemical formulations that meet specific customer requirements.
Revenue is generated through the sale of specialized chemical products across domestic and international markets, serving industrial manufacturers, FMCG brands, and institutional clients.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹697.56 Cr | ₹697.20 Cr |
| Total income | ₹698.16 Cr | ₹697.20 Cr |
| Profit before tax | ₹48.80 Cr | ₹47.67 Cr |
| Profit after tax | ₹38.91 Cr | ₹35.10 Cr |
| EPS | ₹7.02 | ₹6.34 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 5.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 7.0% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.60 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations stood at INR 697.56 crore, showing negligible sequential movement from the INR 697.20 crore reported in Q1 FY27.
Total income reached INR 698.159 crore, bolstered by minor non-operating inflows including INR 0.599 crore of other income and INR 0.882 crore of interest income.
What drove margins
Profit after tax grew by 10.86 percent quarter-on-quarter to INR 38.907 crore, pushing the PAT margin up to 5.58 percent from 5.03 percent in Q1 FY27.
Depreciation and amortization expense was recorded at INR 30.096 crore for the quarter, while finance costs stood at INR 8.677 crore.
04 · Reported developments
What changed operationally
PAT increased by 10.86% QoQ to INR 38.907 crore, reflecting an improvement in net profitability despite flat revenue.
05 · Items worth noticing
The line items that can distort a quick read
The company reported provisions of INR 8.765 crore for the quarter ended September 30, 2026.
06 · Beyond the numbers
What changed beyond the numbers
Reported update
Financial Results Filing
The financial results for Q2 FY27 were submitted through an official exchange XBRL filing, reporting consolidated figures under Indian Accounting Standards (Ind AS).
07 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations remained essentially flat at INR 697.56 crore in Q2 FY27 compared to INR 697.20 crore in Q1 FY27.
PAT rose from INR 35.095 crore in Q1 FY27 to INR 38.907 crore in Q2 FY27, accompanied by an increase in EPS from INR 6.34 to INR 7.02.
08 · Key Q&A
The quarter, answered directly
What does Rossari Biotech do?
Rossari Biotech Limited operates as a specialty chemicals manufacturer, delivering customized chemical solutions across diverse end-user industries including home care, personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition.
What is the clearest takeaway from Q2 FY27?
Rossari Biotech Limited reported consolidated revenue from operations of INR 697.56 crore for the quarter ended September 30, 2026, remaining stable compared to INR 697.20 crore recorded in the preceding quarter ended June 30, 2026.
What drove revenue or demand?
Consolidated revenue from operations stood at INR 697.56 crore, showing negligible sequential movement from the INR 697.20 crore reported in Q1 FY27.
What mattered most for margins or profitability?
Profit after tax grew by 10.86 percent quarter-on-quarter to INR 38.907 crore, pushing the PAT margin up to 5.58 percent from 5.03 percent in Q1 FY27.
What changed operationally beyond the headline numbers?
The financial results for Q2 FY27 were submitted through an official exchange XBRL filing, reporting consolidated figures under Indian Accounting Standards (Ind AS).
What should the next disclosure help confirm?
Monitor subsequent quarterly filings for trends in consolidated revenue growth, margin trajectory, and cash flow performance.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Upcoming Financial Disclosures: Monitor subsequent quarterly filings for trends in consolidated revenue growth, margin trajectory, and cash flow performance.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.